CCP
VKTX icon

Corient Capital Partners’s Viking Therapeutics VKTX Stock Holding History

Corient Capital Partners’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-153,959
Closed -$462K – 767
2022
Q1 		$462K Buy
+153,959
New +$552K 0.03% 406

Other funds holding VKTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.47B AUM 86.42% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Corient Capital Partners's VKTX Position: Q2 2022 in Review

Corient Capital Partners sold out of Viking Therapeutics (VKTX) in Q2 2022, closing a stake of 153,959 shares — an estimated $462K sold.

Corient Capital Partners first reported a position in VKTX in Q1 2022 and held it in 1 quarter. The position peaked at $462K in Q1 2022. 114 funds tracked by Wall St. Rank hold VKTX as of Q2 2022.

  • Corient Capital Partners reported no remaining Viking Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Corient Capital Partners sold 153,959 Viking Therapeutics shares in Q2 2022, an estimated $462K.
  • Corient Capital Partners first reported a position in Viking Therapeutics in Q1 2022 and held it in 1 quarter.
  • Corient Capital Partners's Viking Therapeutics position peaked at $462K in Q1 2022.
  • 114 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2022.

Based on Corient Capital Partners's 13F filing for Q2 2022, filed 12 Aug 2022.